Search

FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

Genfit, developing drugs for NASH, to trade on Nasdaq

GENFIT, DEVELOPING DRUGS FOR NASH, TO TRADE ON NASDAQ

The company, one of several developing drugs for the growing fatty liver disease, said in an SEC filing that it would sell its shares...

 
 
 
Report: College bribery scandal tip stemmed from pharma pump-and-dump investigation

REPORT: COLLEGE BRIBERY SCANDAL TIP STEMMED FROM PHARMA PUMP-AND-DUMP INVESTIGATION

The Wall Street Journal reported that Morrie Tobin tipped off investigators about the college bribery scheme, which ensnared a biotech...

Bio Roundup: Golumbeski's Legacy, CRISPR Moratorium, Rebate Week & More

BIO ROUNDUP: GOLUMBESKI'S LEGACY, CRISPR MORATORIUM, REBATE WEEK & MORE

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb's proposal to buy Celgene for $74 billion...

 
 
 
Gene Therapy Boom, Cracking Alzheimer's: What's Hot on May 21

GENE THERAPY BOOM, CRACKING ALZHEIMER'S: WHAT'S HOT ON MAY 21

Our annual half-day life sciences variety show, “ What's Hot in Biotech ,” is back. Join Xconomy on May 21 at Bristol-Myers Squibb's...

NCI's Norman Sharpless named as acting FDA commissioner to succeed Gottlieb

NCI'S NORMAN SHARPLESS NAMED AS ACTING FDA COMMISSIONER TO SUCCEED GOTTLIEB

Sharpless, the director of the National Cancer Institute, was reportedly favored by HHS Secretary Alex Azar as outgoing Commissioner...

 
 
 
Roche's Tecentriq approved as first immunotherapy drug for breast cancer

ROCHE'S TECENTRIQ APPROVED AS FIRST IMMUNOTHERAPY DRUG FOR BREAST CANCER

The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive...

Clinical trials of Allergan's antidepressant rapastinel fail

CLINICAL TRIALS OF ALLERGAN'S ANTIDEPRESSANT RAPASTINEL FAIL

An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought...

 
 
 
HBO documentary ‘The Inventor' goes inside the rise and fall of Theranos

HBO DOCUMENTARY ‘THE INVENTOR' GOES INSIDE THE RISE AND FALL OF THERANOS

Despite a couple of flaws, Alex Gibney's new film - airing March 18 - expertly portrays how Elizabeth Holmes's dream of changing the...

Report: Purdue Pharma exploring Chapter 11 bankruptcy filing

REPORT: PURDUE PHARMA EXPLORING CHAPTER 11 BANKRUPTCY FILING

Reuters reported Monday that the maker of OxyContin was considering the filing so that it could negotiate claims with plaintiffs in...

 
 
 
GE's new CEO played a key role in unlocking a 'win-win' deal with Danaher

GE'S NEW CEO PLAYED A KEY ROLE IN UNLOCKING A 'WIN-WIN' DEAL WITH DANAHER

General Electric said on Monday it would sell its biopharma business to Danaher in a $21.4 billion transaction - Danaher's largest-ever...

 
 
 
Roche to buy Spark Therapeutics for $4.8 billion

ROCHE TO BUY SPARK THERAPEUTICS FOR $4.8 BILLION

Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.

GE sells biopharma unit for $21 billion

GE SELLS BIOPHARMA UNIT FOR $21 BILLION

BOSTON - General Electric is selling its biopharma business to Danaher Corp. for $21.4 billion as the industrial giant continues to...

 
 
 
People with rare diseases get 'unequal treatment' from 'inflexible' NHS drug regulator, warns report

PEOPLE WITH RARE DISEASES GET 'UNEQUAL TREATMENT' FROM 'INFLEXIBLE' NHS DRUG REGULATOR, WARNS REPORT

A study by MAP BioPharma found only 13 per cent of rare disease medicines made it through The National Institute for Health and Care...

Market Outlook-Leveraging Market Corrections for M&A or IPOs

MARKET OUTLOOK-LEVERAGING MARKET CORRECTIONS FOR M&A OR IPOS

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year of heightened market volatility. Investors'...

 
 
 
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More

BIO ROUNDUP: NEW CRISPR FEUD, A NY SPLASH, PHARMA VS. CONGRESS & MORE

If you're into congressional spectacles, stay tuned later this month. A group of top biopharma executives-the full roster isn't known...

Using Decision Science for Negotiations: Getting to Win-Win

USING DECISION SCIENCE FOR NEGOTIATIONS: GETTING TO WIN-WIN

New medicines often progress from idea to regulatory approval through collaborative licensing agreements or acquisition. Deal-making...

 
 
 
Former Insys execs in alleged opioid conspiracy start criminal trial in Boston

FORMER INSYS EXECS IN ALLEGED OPIOID CONSPIRACY START CRIMINAL TRIAL IN BOSTON

The trial - of Insys founder John Kapoor and four other defendants - had been scheduled to start Monday morning. Two other executives...

Novartis stockpiles drugs amid Brexit supply chain concerns

NOVARTIS STOCKPILES DRUGS AMID BREXIT SUPPLY CHAIN CONCERNS

The Swiss drugmaker is concerned that a no-deal Brexit would disrupt delicate supply chains and urged the UK and EU to provide clarity...